156 related articles for article (PubMed ID: 29803341)
1. Sitagliptin on carotid intima-media thickness in type 2 diabetes patients receiving primary or secondary prevention of cardiovascular disease: A subgroup analysis of the PROLOGUE study.
Tanaka A; Yoshida H; Nanasato M; Oyama JI; Ishizu T; Ajioka M; Ishiki R; Saito M; Shibata Y; Kaku K; Maemura K; Higashi Y; Inoue T; Murohara T; Node K
Int J Cardiol; 2018 Nov; 271():331-335. PubMed ID: 29803341
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial.
Oyama J; Murohara T; Kitakaze M; Ishizu T; Sato Y; Kitagawa K; Kamiya H; Ajioka M; Ishihara M; Dai K; Nanasato M; Sata M; Maemura K; Tomiyama H; Higashi Y; Kaku K; Yamada H; Matsuhisa M; Yamashita K; Bando YK; Kashihara N; Ueda S; Inoue T; Tanaka A; Node K;
PLoS Med; 2016 Jun; 13(6):e1002051. PubMed ID: 27351380
[TBL] [Abstract][Full Text] [Related]
3. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.
Mita T; Katakami N; Shiraiwa T; Yoshii H; Onuma T; Kuribayashi N; Osonoi T; Kaneto H; Kosugi K; Umayahara Y; Yamamoto T; Matsumoto K; Yokoyama H; Tsugawa M; Gosho M; Shimomura I; Watada H;
Diabetes Care; 2016 Mar; 39(3):455-64. PubMed ID: 26822324
[TBL] [Abstract][Full Text] [Related]
4. Differential effect of concomitant antidiabetic agents on carotid atherosclerosis: a subgroup analysis of the PROLOGUE study.
Tanaka A; Kawaguchi A; Oyama JI; Ishizu T; Ito H; Fukui J; Kondo T; Kuroki S; Nanasato M; Higashi Y; Kaku K; Inoue T; Murohara T; Node K
Heart Vessels; 2019 Feb; 34(2):375-384. PubMed ID: 30284018
[TBL] [Abstract][Full Text] [Related]
5. Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE).
Katakami N; Mita T; Irie Y; Takahara M; Matsuoka TA; Gosho M; Watada H; Shimomura I;
Cardiovasc Diabetol; 2018 Feb; 17(1):24. PubMed ID: 29402270
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin on Carotid Intima-Media Thickness in Type 2 Diabetes Mellitus Patients and Anemia: A Subgroup Analysis of the PROLOGUE Study.
Lu Z; Ma G; Chen L
Mediators Inflamm; 2020; 2020():8143835. PubMed ID: 32454794
[TBL] [Abstract][Full Text] [Related]
7. Changes in carotid intima-media thickening in patients with type 2 diabetes mellitus: Subanalysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation.
Mita T; Katakami N; Shiraiwa T; Yoshii H; Gosho M; Shimomura I; Watada H;
J Diabetes Investig; 2017 Mar; 8(2):254-255. PubMed ID: 28256102
[TBL] [Abstract][Full Text] [Related]
8. Sitagliptin on carotid intima-media thickness in type 2 diabetes and hyperuricemia patients: a subgroup analysis of the PROLOGUE study.
Zhao Y; Wang H; Ke D; Deng W; Ji Y; Yang J; Lin Z; Li G; Xiao L; Tang J; Chen Q
Ther Adv Chronic Dis; 2021; 12():20406223211026993. PubMed ID: 34221308
[TBL] [Abstract][Full Text] [Related]
9. Sex-Related Differences in Sitagliptin Treatment in Type 2 Diabetes: Results from the PROLOGUE Trial.
Wu X; Zhang S; Jin Y; Xiao X
Med Sci Monit; 2022 Nov; 28():e938030. PubMed ID: 36444134
[TBL] [Abstract][Full Text] [Related]
10. Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus.
Ishikawa S; Shimano M; Watarai M; Koyasu M; Uchikawa T; Ishii H; Inden Y; Takemoto K; Murohara T
Am J Cardiol; 2014 Aug; 114(3):384-8. PubMed ID: 24929624
[TBL] [Abstract][Full Text] [Related]
11. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
Yamada H; Tanaka A; Kusunose K; Amano R; Matsuhisa M; Daida H; Ito M; Tsutsui H; Nanasato M; Kamiya H; Bando YK; Odawara M; Yoshida H; Murohara T; Sata M; Node K;
Cardiovasc Diabetol; 2017 May; 16(1):63. PubMed ID: 28490337
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Sitagliptin on the Regression of Carotid Intima-Media Thickening in Patients with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation.
Mita T; Katakami N; Shiraiwa T; Yoshii H; Gosho M; Shimomura I; Watada H
Int J Endocrinol; 2017; 2017():1925305. PubMed ID: 28250768
[No Abstract] [Full Text] [Related]
13. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
[TBL] [Abstract][Full Text] [Related]
14. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.
Barbieri M; Rizzo MR; Marfella R; Boccardi V; Esposito A; Pansini A; Paolisso G
Atherosclerosis; 2013 Apr; 227(2):349-54. PubMed ID: 23375680
[TBL] [Abstract][Full Text] [Related]
15. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Mita T; Katakami N; Yoshii H; Onuma T; Kaneto H; Osonoi T; Shiraiwa T; Kosugi K; Umayahara Y; Yamamoto T; Yokoyama H; Kuribayashi N; Jinnouchi H; Gosho M; Shimomura I; Watada H;
Diabetes Care; 2016 Jan; 39(1):139-48. PubMed ID: 26628419
[TBL] [Abstract][Full Text] [Related]
16. Relationship between frequency of hypoglycemic episodes and changes in carotid atherosclerosis in insulin-treated patients with type 2 diabetes mellitus.
Mita T; Katakami N; Shiraiwa T; Yoshii H; Kuribayashi N; Osonoi T; Kaneto H; Kosugi K; Umayahara Y; Gosho M; Shimomura I; Watada H
Sci Rep; 2017 Jan; 7():39965. PubMed ID: 28067320
[TBL] [Abstract][Full Text] [Related]
17. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
[TBL] [Abstract][Full Text] [Related]
18. Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE).
Mita T; Katakami N; Shiraiwa T; Yoshii H; Onuma T; Kuribayashi N; Osonoi T; Kaneto H; Kosugi K; Umayahara Y; Yamamoto T; Matsumoto K; Yokoyama H; Tsugawa M; Gosho M; Shimomura I; Watada H
Diabetol Metab Syndr; 2014 Mar; 6(1):35. PubMed ID: 24607023
[TBL] [Abstract][Full Text] [Related]
19. Dose-Dependent Effect of Sitagliptin on Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Post Hoc Analysis.
Mita T; Katakami N; Shiraiwa T; Yoshii H; Gosho M; Shimomura I; Watada H
Diabetes Ther; 2017 Oct; 8(5):1135-1146. PubMed ID: 28933039
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes.
Li B; Luo YR; Tian F; Chen YD; Tian JW; Ding Y; Zhu M; Li JW; Zhang YQ; Shi WM
Atherosclerosis; 2020 May; 300():10-18. PubMed ID: 32247073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
